School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, Shandong 250022, China.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute-Shandong Cancer Hospital Affiliated to Shandong University, No. 440 Jiyan Road, Jinan 250117, Shandong, China.
Biomed Res Int. 2019 Jan 10;2019:8534761. doi: 10.1155/2019/8534761. eCollection 2019.
The purpose of this study was to assess the diagnostic value of arginine-glycine-aspartic acid (RGD) PET/CT for tumor detection in patients with suspected malignant lesions and to determine the predictive performance of RGD PET/CT in identifying responders. . The PubMed (Medline), EMBASE, Cochrane Library, and Web of Science databases were systematically searched for potentially relevant publications (last updated on July 28th, 2018) reporting the performance of RGD PET in the field of oncology. Pooled sensitivities, specificities, and diagnostic odds ratios (DORs) were calculated for parameters. The areas under the curve (AUCs) and Q⁎ index scores were determined from the constructed summary receiver operating characteristic (SROC) curve. We explored heterogeneity by metaregression. . Nine studies, five including 216 patients that determined diagnostic performance and three including 75 patients that determined the predictive value of parameters, met our inclusion criteria. The pooled sensitivity, pooled specificity, DOR, AUC, and Q⁎ index score of RGD PET/CT for the detection of underlying malignancy were 0.85 (0.79-0.89), 0.93 (0.90-0.96), 48.35 (18.95-123.33), 0.9262 (standard error=0.0216), and 0.8606 for SUVmax and 0.86 (0.80-0.91), 0.92 (0.88-0.94), 40.49 (14.16-115.77), 0.9312 (SE=0.0177), and 0.8665 for SUVmean, respectively. The pooled sensitivity, pooled specificity, DOR, AUC, and Q⁎ index score of RGD PET/CT for identifying responders were 0.80 (0.59-0.93), 0.74 (0.60-0.85), 15.76 (4.33-57.32), 0.8682 (0.0539), and 0.7988, respectively, for SUVmax at baseline. . The interesting but preliminary data in this meta-analysis demonstrate that RGD PET/CT may be an ideal diagnostic tool for detecting underlying malignancies in patients suspected of having tumors and may be able to efficiently predict short-term outcomes.
本研究旨在评估精氨酸-甘氨酸-天冬氨酸（RGD）PET/CT 对疑似恶性病变患者肿瘤检测的诊断价值，并确定 RGD PET/CT 在识别应答者方面的预测性能。通过系统检索 PubMed（Medline）、EMBASE、Cochrane 图书馆和 Web of Science 数据库（截至 2018 年 7 月 28 日更新），筛选出报告 RGD PET 在肿瘤学领域应用的潜在相关文献。对参数进行汇总敏感性、特异性和诊断优势比（DOR）计算。通过构建汇总受试者工作特征（SROC）曲线来确定曲线下面积（AUC）和 Q指数得分。通过荟萃回归探索异质性。纳入 9 项研究，其中 5 项研究包含 216 例患者，用于确定诊断性能，3 项研究包含 75 例患者，用于确定参数的预测价值。RGD PET/CT 检测潜在恶性肿瘤的汇总敏感性、汇总特异性、DOR、AUC 和 SUVmax 的 Q指数得分分别为 0.85（0.79-0.89）、0.93（0.90-0.96）、48.35（18.95-123.33）、0.9262（标准误差=0.0216）和 0.8606，SUVmean 的汇总敏感性、汇总特异性、DOR、AUC 和 Q指数得分分别为 0.86（0.80-0.91）、0.92（0.88-0.94）、40.49（14.16-115.77）、0.9312（SE=0.0177）和 0.8665。RGD PET/CT 用于识别应答者的汇总敏感性、汇总特异性、DOR、AUC 和 SUVmax 的 Q指数得分分别为 0.80（0.59-0.93）、0.74（0.60-0.85）、15.76（4.33-57.32）、0.8682（0.0539）和 0.7988，SUVmean 的汇总敏感性、汇总特异性、DOR、AUC 和 Q*指数得分分别为 0.86（0.80-0.91）、0.74（0.60-0.85）、15.76（4.33-57.32）、0.8682（0.0539）和 0.7988。本荟萃分析的有趣但初步数据表明，RGD PET/CT 可能是一种理想的诊断工具，可用于检测疑似肿瘤患者的潜在恶性肿瘤，并且可能能够有效地预测短期结果。
